Mini-Review: Tregs As a Tool for Therapy-Obvious and Non-Obvious Challenges and Solutions

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2024 Oct 25

PMID 39451198

Authors

Elena I Morgun

Irina A Govorova

Maria B Chernysheva

Maria A Machinskaya

Ekaterina A Vorotelyak

Affiliations

Soon will be listed here.

Abstract

Tregs have the potential to be utilized as a novel therapeutic agent for the treatment of various chronic diseases, including diabetes, Alzheimer's disease, asthma, and rheumatoid arthritis. One of the challenges associated with developing a therapeutic product based on Tregs is the non-selectivity of polyclonal cells. A potential solution to this issue is a generation of antigen-specific CAR-Tregs. Other challenges associated with developing a therapeutic product based on Tregs include the phenotypic instability of these cells in an inflammatory microenvironment, discrepancies between engineered Treg-like cells and natural Tregs, and the expression of dysfunctional isoforms of Treg marker genes. This review presents a summary of proposed strategies for addressing these challenges.

References

Uenishi G, Repic M, Yam J, Landuyt A, Saikumar-Lakshmi P, Guo T . GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes. JCI Insight. 2024; 9(6). PMC: 11063937. DOI: 10.1172/jci.insight.171844. View

Guo J, Zhou X . Regulatory T cells turn pathogenic. Cell Mol Immunol. 2015; 12(5):525-32. PMC: 4579652. DOI: 10.1038/cmi.2015.12. View

Yamazaki S, Patel M, Harper A, Bonito A, Fukuyama H, Pack M . Effective expansion of alloantigen-specific Foxp3+ CD25+ CD4+ regulatory T cells by dendritic cells during the mixed leukocyte reaction. Proc Natl Acad Sci U S A. 2006; 103(8):2758-63. PMC: 1413800. DOI: 10.1073/pnas.0510606103. View

Kristensen B, Hegedus L, Madsen H, Smith T, Nielsen C . Altered balance between self-reactive T helper (Th)17 cells and Th10 cells and between full-length forkhead box protein 3 (FoxP3) and FoxP3 splice variants in Hashimoto's thyroiditis. Clin Exp Immunol. 2014; 180(1):58-69. PMC: 4367094. DOI: 10.1111/cei.12557. View

Sato Y, Nathan A, Shipp S, Wright J, Tate K, Wani P . knockout-humanized mouse model for pre-clinical safety and efficacy evaluation of Treg-like cell products. Mol Ther Methods Clin Dev. 2023; 31:101150. PMC: 10679769. DOI: 10.1016/j.omtm.2023.101150. View

Sato Y, Liu J, Lee E, Perriman R, Roncarolo M, Bacchetta R . Co-Expression of FOXP3FL and FOXP3Δ2 Isoforms Is Required for Optimal Treg-Like Cell Phenotypes and Suppressive Function. Front Immunol. 2021; 12:752394. PMC: 8560788. DOI: 10.3389/fimmu.2021.752394. View

Caplan H, Prabhakara K, Toledano Furman N, Zorofchian S, Martin C, Xue H . Human-derived Treg and MSC combination therapy may augment immunosuppressive potency in vitro, but did not improve blood brain barrier integrity in an experimental rat traumatic brain injury model. PLoS One. 2021; 16(5):e0251601. PMC: 8153465. DOI: 10.1371/journal.pone.0251601. View

Marek-Trzonkowska N, Mysliwiec M, Iwaszkiewicz-Grzes D, Gliwinski M, Derkowska I, Zalinska M . Factors affecting long-term efficacy of T regulatory cell-based therapy in type 1 diabetes. J Transl Med. 2016; 14(1):332. PMC: 5131539. DOI: 10.1186/s12967-016-1090-7. View

Mansilla M, Presas-Rodriguez S, Teniente-Serra A, Gonzalez-Larreategui I, Quirant-Sanchez B, Fondelli F . Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy. Cell Mol Immunol. 2021; 18(6):1353-1374. PMC: 8167140. DOI: 10.1038/s41423-020-00618-z. View

10.

Miyabe C, Miyabe Y, Strle K, Kim N, Stone J, Luster A . An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy. Ann Rheum Dis. 2016; 76(5):898-905. PMC: 5744591. DOI: 10.1136/annrheumdis-2016-210070. View

11.

Spanier J, Fung V, Wardell C, Alkhatib M, Chen Y, Swanson L . Tregs with an MHC class II peptide-specific chimeric antigen receptor prevent autoimmune diabetes in mice. J Clin Invest. 2023; 133(18). PMC: 10503798. DOI: 10.1172/JCI168601. View

12.

Ryba-Stanislawowska M, Skrzypkowska M, Mysliwska J, Mysliwiec M . The serum IL-6 profile and Treg/Th17 peripheral cell populations in patients with type 1 diabetes. Mediators Inflamm. 2013; 2013:205284. PMC: 3595664. DOI: 10.1155/2013/205284. View

13.

Dabrowska A, Grubba M, Balihodzic A, Szot O, Sobocki B, Perdyan A . The Role of Regulatory T Cells in Cancer Treatment Resistance. Int J Mol Sci. 2023; 24(18). PMC: 10531820. DOI: 10.3390/ijms241814114. View

14.

Tenspolde M, Zimmermann K, Weber L, Hapke M, Lieber M, Dywicki J . Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes. J Autoimmun. 2019; 103:102289. DOI: 10.1016/j.jaut.2019.05.017. View

15.

Yang H, Park S, Baek H, Lee C, Chung G, Liu X . Adoptive therapy with amyloid-β specific regulatory T cells alleviates Alzheimer's disease. Theranostics. 2022; 12(18):7668-7680. PMC: 9706584. DOI: 10.7150/thno.75965. View

16.

Blinova V, Zhdanov D . Many Faces of Regulatory T Cells: Heterogeneity or Plasticity?. Cells. 2024; 13(11. PMC: 11171907. DOI: 10.3390/cells13110959. View

17.

Nayer B, Tan J, Alshoubaki Y, Lu Y, Legrand J, Lau S . Local administration of regulatory T cells promotes tissue healing. Nat Commun. 2024; 15(1):7863. PMC: 11383969. DOI: 10.1038/s41467-024-51353-2. View

18.

Stucchi A, Maspes F, Montee-Rodrigues E, Fousteri G . Engineered Treg cells: The heir to the throne of immunotherapy. J Autoimmun. 2023; 144:102986. DOI: 10.1016/j.jaut.2022.102986. View

19.

Chen C, Hu N, Wang J, Xu L, Jia X, Fan X . Umbilical cord mesenchymal stem cells promote neurological repair after traumatic brain injury through regulating Treg/Th17 balance. Brain Res. 2021; 1775:147711. DOI: 10.1016/j.brainres.2021.147711. View

20.

Skuljec J, Chmielewski M, Happle C, Habener A, Busse M, Abken H . Chimeric Antigen Receptor-Redirected Regulatory T Cells Suppress Experimental Allergic Airway Inflammation, a Model of Asthma. Front Immunol. 2017; 8:1125. PMC: 5600908. DOI: 10.3389/fimmu.2017.01125. View